KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

ImmunityBio responds to FDA concerns over promotional content

Stipple Bio raises $100M Series A to advance next-gen cancer therapies

The new capital is expected to fund the company through 2029

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy

The trial also demonstrated significant improvements across multiple secondary endpoints

Alkem enters daily wellness space with launch of 'A to Z Daily' multivitamin

New adult supplement combines 26 vitamins, minerals and botanicals to address stress, energy, immunity and cognitive wellness in one daily tablet

Zydus gets USFDA final approval for generic Dapagliflozin with 180-day shared exclusivity

Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility

MedGenome’s RNA-based NGS study sharpens sarcoma diagnosis, alters treatment in 25% cases

India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases

Symeres and Ambagon team up to target ‘undruggable’ proteins in colorectal cancer

Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies